lung-cancer

Documents about lung-cancer

• Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC#353285ClinicalTrials.gov
• Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)#363605ClinicalTrials.gov
• Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non–Small Cell Lung Cancer#370802HAL (France)
• MiracleNet: A Biologically Interpretable Machine Learning Model for Resected Non-small-cell Lung Cancer.#371403NCBI PubMed Central
• Lung cancer organoids for functional precision oncology: from disease modeling to clinical decision support.#371434NCBI PubMed Central
• Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects#377410ClinicalTrials.gov
• Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy#377429ClinicalTrials.gov
• Integrating Ant Colony Optimization with Deep Learning for Improved Lung Cancer Diagnosis and Prognosis.#385200NCBI PubMed Central
• Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases#394765ClinicalTrials.gov
• Phantom-based evaluation of radiomics feature stability for low-dose CT lung cancer screening.#430995NCBI PubMed Central
• The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China#442086ClinicalTrials.gov
• A Quantitative Comparison between Shannon and Tsallis–Havrda–Charvat Entropies Applied to Cancer Outcome Prediction#308340HAL (France)
• Immunité de la métastase osseuse et effets de l'utilisation d'inhibiteurs de check point immunitaires#257660HAL (France)
• PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy#356479ClinicalTrials.gov
• To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)#290995ClinicalTrials.gov
• Brain Metabolic Activity Measured by [ ¹⁸ F]FDG PET/CT Predicts Survival in Patients with Advanced Non–Small Cell Lung Cancer#159306HAL (France)
• Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer#256863ClinicalTrials.gov
• Bacterial taxa associated with lung cancer cases in Southeast Asians: a pilot case-control study.#3912NCBI PubMed Central
• Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy#125813ClinicalTrials.gov
• First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy#158205ClinicalTrials.gov
• IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed#172289ClinicalTrials.gov
• The NMD Pathway Regulates GABARAPL1 mRNA during the EMT#175774HAL (France)
• Understanding Public Perceptions of Lung Cancer in China: Infodemiology Study of Baidu Index and Weibo Posts#176756DOAJ
• A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients#184840ClinicalTrials.gov
• State law at the intersection of lung cancer screening guidelines and social determinants of health.#186094NCBI PubMed Central
• Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC#217007ClinicalTrials.gov
• Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer#218146HAL (France)
• Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes#238131ClinicalTrials.gov
• Data Management and Sharing Plan for: Assessing Equity in Shared Decision Making, Utilization, and Outcomes of Lung Cancer Screening#263858UNC Dataverse Dataverse OAI Archive
• Application of organoid models in basic and translational research of lung cancer: a narrative review.#281031NCBI PubMed Central
• Circulating cell populations as response predictors and targets to improve immunotherapy in metastatic lung cancer.#281034NCBI PubMed Central
• Using an Integrated, Digital Framework to Standardize and Expand a Multisite Lung Cancer Screening Program.#312674NCBI PubMed Central
• Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD#321693ClinicalTrials.gov
• A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC#325288ClinicalTrials.gov
• Dosimetric comparison between laterality-specific and general knowledge-based planning models for nonsmall cell lung cancer.#327044NCBI PubMed Central
• KMT2D loss drives adeno-to-squamous transition and sensitizes TKI-resistant lung cancer to AURKA inhibition.#354686NCBI PubMed Central
• DC Vaccine Combined With CIK Cells in Patients With SCLC#377285ClinicalTrials.gov
• The current status of health literacy among caregivers of lung cancer patients:A cross-sectional survey.#395852NCBI PubMed Central
• 68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC#411396ClinicalTrials.gov
• Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)#411407ClinicalTrials.gov
• Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)#414502ClinicalTrials.gov
• Specific PET Imaging for Precision Management of Lung Cancer: Advances, Clinical Translation and Future Directions.#415381NCBI PubMed Central
• PET/CT Radiogenomic Mutation Prediction in Non-Small Cell Lung Cancer Using Multi-Label Learning#441800arXiv CS
• Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.#208451ClinicalTrials.gov
• Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant Immunotherapy#249588ClinicalTrials.gov
• Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)#208463ClinicalTrials.gov
• A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies#287543ClinicalTrials.gov
• Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors#300272ClinicalTrials.gov
• Side Effects of Anti-PD-(L)-1 and Anti CTLA-A4 in the Non Small Cells Lung Cancer#148740ClinicalTrials.gov
• Repurposing Bromhexine to Suppress Non-Small Cell Lung Cancer Growth by Inhibiting Methylenetetrahydrofolate dehydrogenase 2 - Dataset#196685Figshare